# Climb Bio Inc. (CLYM) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $15.52, market value $891 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Climb Bio Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 3.7×**. The shares trade at 3.7× book value; book value is a meaningful part of the valuation.

## Profitability
- **Return on equity: -37.3%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): 42.5%**. Earnings per share rose 42.5%.

## Financial health
- **Current ratio: 15.16** (quick 15.16). Current assets cover the next year's liabilities 15.16 times.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Climb Bio Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (14 analysts). 14 analysts cover Climb Bio Inc.; the consensus is strong_buy, with an average price target of $22.86 (+47% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 566.1%** (YTD 288.0%, 3-mo 47.1%). The shares are up 566.1% over twelve months including dividends.
- **From 52-week high: -15.3%** (907.8% above the low). Trading 15% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 54**. An RSI of 54 is neutral.
- **Beta (1 yr): 1.81** (volatility 97%). Beta of 1.81 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CLYM · Page: https://foliofundamentals.com/stocks/clym

Not investment advice.